<li>almotriptan<p>venlafaxine, almotriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>azithromycin<p>azithromycin and venlafaxine both increase  QTc interval. Minor/Significance Unknown.</p></li><li>bumetanide<p>bumetanide, venlafaxine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>celandine<p>celandine decreases effects of venlafaxine by pharmacodynamic antagonism. Minor/Significance Unknown. Based on animal studies.</p></li><li>codeine<p>venlafaxine decreases effects of codeine by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of codeine to active metabolite morphine.</p></li><li>dexfenfluramine<p>venlafaxine will increase the level or effect of dexfenfluramine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>dexmethylphenidate<p>dexmethylphenidate increases effects of venlafaxine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>donepezil<p>venlafaxine will increase the level or effect of donepezil by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>eletriptan<p>venlafaxine, eletriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>encainide<p>venlafaxine will increase the level or effect of encainide by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>ethacrynic acid<p>ethacrynic acid, venlafaxine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>fesoterodine<p>venlafaxine will increase the level or effect of fesoterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>fluoxetine<p>venlafaxine will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>frovatriptan<p>venlafaxine, frovatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>furosemide<p>furosemide, venlafaxine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>galantamine<p>venlafaxine will increase the level or effect of galantamine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>hydrocodone<p>venlafaxine decreases effects of hydrocodone by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of hydrocodone to active metabolite morphine.</p></li><li>lithium<p>venlafaxine, lithium. Mechanism: unknown. Minor/Significance Unknown. Risk of neurotoxicity.</p></li><li>methylphenidate<p>methylphenidate increases effects of venlafaxine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>naratriptan<p>venlafaxine, naratriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>oxycodone<p>venlafaxine decreases effects of oxycodone by decreasing metabolism. Minor/Significance Unknown. Decreased conversion of oxycodone to active metabolite morphine.</p></li><li>panax ginseng<p>panax ginseng increases effects of venlafaxine by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>paroxetine<p>venlafaxine will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>pazopanib<p>pazopanib and venlafaxine both increase  QTc interval. Minor/Significance Unknown.</p></li><li>perhexiline<p>venlafaxine will increase the level or effect of perhexiline by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>pleurisy root<p>pleurisy root decreases effects of venlafaxine by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.</p></li><li>promazine<p>venlafaxine will increase the level or effect of promazine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>rizatriptan<p>venlafaxine, rizatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan<p>venlafaxine, sumatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan intranasal<p>venlafaxine, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>sumatriptan transdermal<p>venlafaxine, sumatriptan transdermal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li><li>tolterodine<p>venlafaxine will increase the level or effect of tolterodine by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>torsemide<p>torsemide, venlafaxine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>tropisetron<p>venlafaxine will increase the level or effect of tropisetron by  affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.</p></li><li>zolmitriptan<p>venlafaxine, zolmitriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.</p></li>